Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730182 | 0.77 | TGFBR1 (0.64) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 | |
| SCHEMBL19998624 | 0.77 | USP30 (0.46) | DYRK1ATGFBR1COMTBRD4USP30 | |
| SCHEMBL3850087 | 0.76 | TGFBR1 (0.49) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 | |
| SCHEMBL17930295 | 0.75 | TGFBR1 (0.64) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 | |
| SCHEMBL8948378 | 0.75 | TGFBR1 (0.50) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 | |
| SCHEMBL14826052 | 0.74 | DYRK1A (0.85) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 | |
| SCHEMBL1832961 | 0.72 | DYRK1A (0.58) | DYRK1ATGFBR1TGFBR2KEAP1 | |
| SCHEMBL14996594 | 0.71 | SMN1; SMN2 (0.51) | TGFBR1HPGDNFKB1HSD17B10COMT | |
| SCHEMBL15849392 | 0.71 | TGFBR1 (0.49) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 | |
| SCHEMBL25148828 | 0.71 | TGFBR1 (0.46) | DYRK1ATGFBR1PDE4APDE3ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| EP-3277677-B1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | DYRK1A 3140/4885TGFBR1 4011/4885PDE4A 2431/4885 |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | DYRK1A 2639/4885TGFBR1 4059/4885PDE4A 2183/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | DYRK1A 2639/4885TGFBR1 4059/4885PDE4A 2183/4885 |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | DYRK1A 2631/4885TGFBR1 4013/4885PDE4A 2065/4885 |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | DYRK1A 3140/4885TGFBR1 4011/4885PDE4A 2431/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | DYRK1A 2639/4885TGFBR1 4059/4885PDE4A 2183/4885 |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | DYRK1A 2639/4885TGFBR1 4059/4885PDE4A 2183/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | DYRK1A 2639/4885TGFBR1 4059/4885PDE4A 2183/4885 |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | DYRK1A 2639/4885TGFBR1 4059/4885PDE4A 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.